Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Marina S. Lebedkina"'
Autor:
Daria S. Fomina, Olga A. Mukhina, Valeria I. Mikhailova, Marina S. Lebedkina, Elizaveta L. Sedova, Elena N. Bobrikova, Olga G. Elisyutina, Elena S. Fedenko, Tair T. Nurpeisov, Alexander V. Karaulov, Mar’yana A. Lysenko, Luis Felipe C. Ensina
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed. This study endeavors to assess the practical impact and safety of upadacitinib in pat
Externí odkaz:
https://doaj.org/article/8a93099ff0bf454dbc4f521616c8cb52
Autor:
Daria S. Fomina, Sergey V. Fedosenko, Elena N. Bobrikova, Anton A. Chernov, Olga A. Mukhina, Marina S. Lebedkina, Alexander V. Karaulov, Asel Yu. Nurtazina, Mariana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 95, Iss 7, Pp 568-573 (2023)
Background. Dupilumab, a fully human monoclonal antibody directed against the common -subunit of interleukin (IL)-4 receptors and blocking signaling from both IL-4 and IL-13, may be recommended for the treatment of moderate to severe atopic dermatiti
Externí odkaz:
https://doaj.org/article/65e68e2d00ba4c998efe7da08dfc2317
Autor:
Marina S. Lebedkina, Daria S. Fomina, Zinaida Y. Mutovina, Ulyana A. Mаrkina, Pavel O. Bogomolov, Vladimir P. Chulanov, Mariana A. Lysenko, Ekaterina I. Alexeeva
Publikováno v:
Терапевтический архив, Vol 95, Iss 6, Pp 494-499 (2023)
Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings. Materials and methods. A non-
Externí odkaz:
https://doaj.org/article/eb72a7ef09da4ff099f9522bed183bf7
Autor:
Daria S. Fomina, Marina S. Lebedkina, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Alexander V. Karaulov, Maryana A. Lysenko, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Several virus-neutralizing monoclonal antibodies (mAbs) have become new tools in the treatment of the coronavirus disease (COVID-19), but their effectiveness against the rapidly mutating virus is questionable. The present study investigated the effec
Externí odkaz:
https://doaj.org/article/670820e7fe5d4672ba2d2ca795a32834
Autor:
Anna A. Roppelt, Marina S. Lebedkina, Anton A. Chernov, Tatiana S. Kruglova, Olga A. Mukhina, Yulia D. Yukhnovskaya, Farida A. Samedova, Ulyana A. Mаrkina, Gerelma V. Andrenova, Alexander V. Karaulov, Mariana A. Lysenko, Daria S. Fomina
Publikováno v:
Терапевтический архив, Vol 95, Iss 1, Pp 78-84 (2023)
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/
Externí odkaz:
https://doaj.org/article/2d43eed5d4bf4eb69941f07a641d44c2
Autor:
Daria S. Fomina, Marina S. Lebedkina, Anton A. Chernov, Ekaterina A. Nikitina, Olga A. Mukhina, Valeriya I. Mikhaylova
Publikováno v:
Consilium Medicum, Vol 24, Iss 8, Pp 552-557 (2022)
Background. Many factors influence the development of atopic dermatitis (AD): genetic, environmental (including exposure to allergens), skin barrier damage, and activation of the T2-pathway immune response. Patients with AD, including those with seve
Externí odkaz:
https://doaj.org/article/afab8cc27ade4a79bdbfb4f5797a7e4e
Autor:
Ekaterina A. Nikitina, Daria S. Fomina, Ulyana A. Markina, Sergey S. Andreev, Yuri V. Streltsov, Tatiana S. Kruglova, Marina S. Lebedkina, Alexander V. Karaulov, Maryana A. Lysenko
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, potentially life-threatening syndromes characterized by the development of necrotic epidermal and mucosal lesions. The most common etiologic cause of SJS/TEN is drug-induce
Externí odkaz:
https://doaj.org/article/a2672194f8cd4f73843ec3187797f6e0
Autor:
Ulyana A. Markina, Daria S. Fomina, Marina S. Lebedkina, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva, Zinaida Yu. Mutovina, Alexander V. Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 94, Iss 5, Pp 675-682 (2022)
Background. The use of virus-neutralizing monoclonal antibodies is an effective method of etiotropic therapy for SARS-CoV-2 in patients of high-risk groups of severe COVID-19. Regdanvimab is a single-component monoclonal antibodies immunoglobulin G1,
Externí odkaz:
https://doaj.org/article/1ca7266523cb42cb8962e01de2e8c208
Autor:
Daria S. Fomina, Olga A. Mukhina, Marina S. Lebedkina, Elena N. Bobrikova, Dmitry O. Sinyavkin, Anton A. Chernov, Valeriya I. Mikhailova
Publikováno v:
Consilium Medicum, Vol 24, Iss 3, Pp 170-176 (2022)
Background. Fungal sensitization (FS) often escapes the attention of clinicians when assessing the spectrum of sensitization in patients with atopic diseases. According to cohort studies is found in 310% of the general population and in 720% of asthm
Externí odkaz:
https://doaj.org/article/b2da650f45a144b7a2ffe748ef663dfc
Autor:
Daria S. Fomina, Olga A. Mukhina, Marina S. Lebedkina, Mirada K. Gadzhieva, Elena N. Bobrikova, Dmitry O. Sinyavkin, Vasiliy V. Parshin, Anton A. Chernov, Andrey S. Belevskiy
Publikováno v:
Терапевтический архив, Vol 94, Iss 3, Pp 413-419 (2022)
Introduction. Guidelines on Biological Therapy for Bronchial Asthma of the European Academy of Allergy and Clinical Immunology (EAACI) identified a number of controversial issues for additional outcome analysis using randomized clinical trials and da
Externí odkaz:
https://doaj.org/article/af3d9eb1ce6446daa7ece9b26896ff20